Home > Journals > Minerva Endocrinology > Past Issues > Minerva Endocrinology 2021 September;46(3) > Minerva Endocrinology 2021 September;46(3):325-34

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

REVIEW   

Minerva Endocrinology 2021 September;46(3):325-34

DOI: 10.23736/S2724-6507.21.03527-2

Copyright © 2021 EDIZIONI MINERVA MEDICA

language: English

Bone quality in hypoparathyroidism

Yu-Kwang D. TAY 1, Gaia TABACCO 2, John P. BILEZIKIAN 3

1 Department of General Medicine, Sengkang General Hospital, Singhealth, Singapore; 2 Unit of Endocrinology and Diabetes, Department of Medicine, Campus Bio-Medico University, Rome, Italy; 3 Unit of Metabolic Bone Disease, Division of Endocrinology, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA



Hypoparathyroidism is a rare disorder characterized by hypocalcemia and deficient or absent levels of parathyroid hormone. The consequences of chronic hypoparathyroidism involve classic target organs of parathyroid hormone, namely the skeleton and the kidneys. In this article, we focus on the abnormalities in bone quality that are associated with hypoparathyroidism. As assessed by several modalities, bone quality is compromised. The evidence for abnormal bone quality includes findings from bone histomorphometry, bone material properties, and high-resolution peripheral computed tomography. These abnormalities include low bone turnover, altered skeletal microarchitecture and bone material properties. How these abnormalities relate to fracture risk are under investigation. In this study, we also reviewed the therapeutic effects of parathyroid hormone as replacement therapy in this disease.


KEY WORDS: Hypoparathyroidism; Bone and bones; Hypocalcemia

top of page